BIOMAT Database Logo BIOMAT Database Logo

Effects of SR 48692, a selective non-peptide neurotensin receptor antagonist, on two dopamine-dependent behavioural responses in mice and rats. 1994

M Poncelet, and J Souilhac, and C Gueudet, and J P Terranova, and D Gully, and G Le Fur, and P Soubrié
Sanofi Recherche, Neuropsychiatry Department, Montpellier, France.

One major mechanism underlying the central action of neurotensin is an interaction with the function of dopamine (DA)-containing neurons. In addition, direct or indirect DA agonists have been reported to promote neurotensin release. We have found that SR 48692, a non-peptide neurotensin receptor antagonist (0.04-0.64 mg/kg orally), antagonizes (50-65%) yawning induced by apomorphine (0.07 mg/kg SC) or bromocriptine (2 mg/kg IP) in rats, and turning behaviour induced by intrastriatal injection of apomorphine (0.25 micrograms), (+) SKF 38393 (0.1 micrograms), bromocriptine (0.01 ng) or (+) amphetamine (10 micrograms) in mice. Other apomorphine-induced effects in mice and rats such as climbing, hypothermia, hypo- and hyper-locomotion, penile erections and stereotypies were not significantly modified by SR 48692. Taken together, these data suggest that neurotensin may play a permissive role in the expression of some but not all behavioural responses to DA receptor stimulation.

UI MeSH Term Description Entries
D008297 Male Males
D009043 Motor Activity Body movements of a human or an animal as a behavioral phenomenon. Activities, Motor,Activity, Motor,Motor Activities
D010410 Penile Erection The state of the PENIS when the erectile tissue becomes filled or swollen (tumid) with BLOOD and causes the penis to become rigid and elevated. It is a complex process involving CENTRAL NERVOUS SYSTEM; PERIPHERAL NERVOUS SYSTEMS; HORMONES; SMOOTH MUSCLES; and vascular functions. Tumescence, Penile,Nocturnal Penile Tumescence,Penile Tumescence,Erection, Penile,Penile Tumescence, Nocturnal,Tumescence, Nocturnal Penile
D011720 Pyrazoles Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
D011804 Quinolines
D001971 Bromocriptine A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion. 2-Bromoergocryptine,Bromocryptin,2-Bromo-alpha-ergocryptine,2-Bromo-alpha-ergokryptine,2-Bromoergocryptine Mesylate,2-Bromoergocryptine Methanesulfonate,2-Bromoergokryptine,Bromocriptin,Bromocriptine Mesylate,CB-154,Parlodel,2 Bromo alpha ergocryptine,2 Bromo alpha ergokryptine,2 Bromoergocryptine,2 Bromoergocryptine Mesylate,2 Bromoergocryptine Methanesulfonate,2 Bromoergokryptine,CB 154,CB154,Mesylate, 2-Bromoergocryptine,Mesylate, Bromocriptine,Methanesulfonate, 2-Bromoergocryptine
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

M Poncelet, and J Souilhac, and C Gueudet, and J P Terranova, and D Gully, and G Le Fur, and P Soubrié
SR 48692, a non-peptide neurotensin receptor antagonist, blocks the cardiovascular effects elicited by neurotensin in guinea pigs.
January 1994, Life sciences,
M Poncelet, and J Souilhac, and C Gueudet, and J P Terranova, and D Gully, and G Le Fur, and P Soubrié
The neurotensin antagonist SR 48692 fails to modify the behavioural responses to a dopamine D1 receptor agonist in the rat.
January 1997, Neuropharmacology,
M Poncelet, and J Souilhac, and C Gueudet, and J P Terranova, and D Gully, and G Le Fur, and P Soubrié
SR 48692, a non-peptide neurotensin receptor antagonist differentially affects neurotensin-induced behaviour and changes in dopaminergic transmission.
April 1994, Neuroscience,
M Poncelet, and J Souilhac, and C Gueudet, and J P Terranova, and D Gully, and G Le Fur, and P Soubrié
A neurotensin antagonist, SR 48692, inhibits colonic responses to immobilization stress in rats.
October 1996, Proceedings of the National Academy of Sciences of the United States of America,
M Poncelet, and J Souilhac, and C Gueudet, and J P Terranova, and D Gully, and G Le Fur, and P Soubrié
The neurotensin receptor antagonist SR 48692 decreases extracellular striatal GABA in rats.
August 1996, Brain research,
M Poncelet, and J Souilhac, and C Gueudet, and J P Terranova, and D Gully, and G Le Fur, and P Soubrié
Differential effects of the nonpeptide neurotensin antagonist, SR 48692, on the pharmacological effects of neurotensin agonists.
January 1995, Peptides,
M Poncelet, and J Souilhac, and C Gueudet, and J P Terranova, and D Gully, and G Le Fur, and P Soubrié
SR 48692, a specific neurotensin receptor antagonist, has no effect on oesophageal motility in humans.
April 2004, Alimentary pharmacology & therapeutics,
M Poncelet, and J Souilhac, and C Gueudet, and J P Terranova, and D Gully, and G Le Fur, and P Soubrié
Neurotensin receptor-mediated inhibition of pancreatic cancer cell growth by the neurotensin antagonist SR 48692.
January 1999, Anticancer research,
M Poncelet, and J Souilhac, and C Gueudet, and J P Terranova, and D Gully, and G Le Fur, and P Soubrié
The nonpeptide neurotensin antagonist, SR 48692, used as a tool to reveal putative neurotensin receptor subtypes.
June 1994, British journal of pharmacology,
M Poncelet, and J Souilhac, and C Gueudet, and J P Terranova, and D Gully, and G Le Fur, and P Soubrié
Effect of the nonpeptide neurotensin antagonist, SR 48692, and two enantiomeric analogs, SR 48527 and SR 49711, on neurotensin binding and contractile responses in guinea pig ileum and colon.
October 1994, The Journal of pharmacology and experimental therapeutics,
Copied contents to your clipboard!